PharmaResearch Hits Another Record on Rejuran as Q2 Growth Momentum Returns

PharmaResearch has again delivered record results, supported by Rejuran, according to an analysis cited by hankyung.com. The key point of the report is that Rejuran was identified as a major driver of the company’s improved performance, while the possible return of growth momentum in the second quarter is drawing attention. The company’s latest trend is being viewed through both the performance of its flagship product and its quarterly growth path. However, the original information does not provide specific revenue or profit figures. Investors are expected to watch whether Rejuran-led earnings strength continues and whether second-quarter growth momentum resumes. Source: hankyung.com